Swiss National Bank
CCCC icon

Swiss National Bank’s C4 Therapeutics CCCC Stock Holding History

Swiss National Bank’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-73,900
Closed -$232K – 2615
2023
Q1 		$232K Sell
73,900
-8,700
-11% -$51.2K ﹤0.01% 2631
2022
Q4 		$487K Buy
82,600
+2,200
+3% +$18.2K ﹤0.01% 2579
2022
Q3 		$705K Hold
80,400
– – ﹤0.01% 2467
2022
Q2 		$606K Buy
80,400
+51,600
+179% +$454K ﹤0.01% 2565
2022
Q1 		$699K Buy
28,800
+2,100
+8% +$51K ﹤0.01% 2528
2021
Q4 		$860K Buy
26,700
+2,900
+12% +$115K ﹤0.01% 2531
2021
Q3 		$1.06M Hold
23,800
– – ﹤0.01% 2411
2021
Q2 		$901K Buy
+23,800
New +$852K ﹤0.01% 2517

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Swiss National Bank's CCCC Position: Q2 2023 in Review

Swiss National Bank sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 73,900 shares — an estimated $232K sold.

Swiss National Bank first reported a position in CCCC in Q2 2021 and held it in 8 quarters. The position peaked at $1.06M in Q3 2021. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Swiss National Bank reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Swiss National Bank sold 73,900 C4 Therapeutics shares in Q2 2023, an estimated $232K.
  • Swiss National Bank first reported a position in C4 Therapeutics in Q2 2021 and held it in 8 quarters.
  • Swiss National Bank's C4 Therapeutics position peaked at $1.06M in Q3 2021.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.